Stock Alert: Novavax Begins Phase 1/2 Clinical Trial Of COVID-19 Vaccine; Stock Up 18% In Premarket

Shares of Novavax Inc. (NVAX) is soaring over 18% in pre-market today, after the biotechnology company announced the commencement of Phase 1/2 clinical trial of its COVID-19 vaccine.